UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 27, 2015
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware |
|
001-34637 |
|
20-1852016 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
25801 Industrial Boulevard, Suite B, Hayward, California |
|
94545 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On January 27, 2015, Anthera Pharmaceuticals, Inc. (the Company) entered into Subscription Agreements (the Subscription
Agreements) with each of Zenyaku Kogyo Co., Ltd. (Zenyaku) and Amgen Inc. (Amgen), with respect to a registered direct offering conducted without an underwriter or placement agent (the Registered Direct
Offering) of an aggregate of 3,216,646 shares of the Companys common stock, par value $0.001 per share (the Common Stock), at an aggregate purchase price of $8,000,000. Pursuant to the Subscription Agreements, Zenyaku will
purchase 2,795,895 shares of Common Stock at a price per share equal to $2.50367, and Amgen will purchase 420,751 shares of Common Stock at a price per share equal to $2.3767, with the consideration to be paid by Amgen in the form of a waiver of a
fee otherwise payable to Amgen pursuant to that certain License Agreement dated December 18, 2007 between Anthera and Amgen (as amended).
Net proceeds from the offering, after deducting estimated offering expenses, are expected to be approximately $6,965,000. The Company intends
to use the net proceeds for general corporate purposes. The closing of the offering is expected to occur on or around January 28, 2015.
The sale of the Common Stock is to be made pursuant to the Companys Registration Statement on Form S-3 (Registration
No. 333-187780) (the Registration Statement), including a prospectus supplement dated January 28, 2015 to the prospectus contained therein, filed by the Company with the Securities and Exchange Commission (the SEC),
pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, on April 5, 2013 and declared effective by the SEC on April 18, 2013.
A copy of the legal opinion of Goodwin Procter LLP, relating to the validity of the shares issued in the Registered Direct Offering, is filed
as Exhibit 5.1 to this report and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.
Item 9.01. Financial Statements and Exhibits.
|
|
|
5.1 |
|
Opinion of Goodwin Procter LLP |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 28, 2015 |
|
|
|
Anthera Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
|
By: |
|
/s/ May Liu |
|
|
|
|
|
|
May Liu |
|
|
|
|
|
|
Principal Accounting Officer and Senior Vice President, Finance and Administration |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
5.1 |
|
Opinion of Goodwin Procter LLP |
Exhibit 5.1
|
|
|
|
|
|
|
|
|
Goodwin Procter LLP
Counselors at Law Three
Embarcadero Center 24th Floor
San Francisco, CA 94111
415-733-6000 |
January 28, 2015
Anthera
Pharmaceuticals, Inc.
25801 Industrial Blvd, Suite B
Hayward, CA 94545
Re: Securities Registered under
Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-3 (File No. 333-187780) (as amended
or supplemented, the Registration Statement) filed on April 5, 2013 with the Securities and Exchange Commission (the Commission) pursuant to the Securities Act of 1933, as amended (the
Securities Act), relating to the registration of the offer by Anthera Pharmaceuticals, Inc., a Delaware corporation (the Company) of up to $100,000,000 of any combination of securities of the types
specified therein. The Registration Statement was declared effective by the Commission on April 18, 2013. Reference is made to our opinion letter dated April 5, 2013 and included as Exhibit 5.1 to the Registration Statement. We are
delivering this supplemental opinion letter in connection with the prospectus supplement (the Prospectus Supplement) filed on January 28, 2015 by the Company with the Commission pursuant to Rule 424 under the Securities Act. The
Prospectus Supplement relates to the offering by the Company of up to 3,216,646 shares of the Companys Common Stock, par value $0.001 per share (the Shares) covered by the Registration Statement. We understand that
the Shares are to be offered and sold in the manner described in the Prospectus Supplement.
We have reviewed such documents and made such
examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on
certificates of officers of the Company.
The opinion set forth below is limited to the Delaware General Corporation Law (which includes
reported judicial decisions interpreting the Delaware General Corporation Law).
Based on the foregoing, we are of the opinion that the
Shares have been duly authorized and, when the price and other terms upon which the Shares are to be sold have been approved by the Board of Directors of the Company (or a duly authorized committee of the Board of Directors) and the Shares have been
issued and delivered against payment in accordance with such terms, the Shares will be validly issued, fully paid and non-assessable.
Anthera Pharmaceuticals, Inc.
January 28, 2015
Page 2
We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration
Statement and to the references to our firm under the caption Legal Matters in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of
the Securities Act or the rules and regulations thereunder.
|
Very truly yours, |
|
/s/ Goodwin Procter LLP |
|
GOODWIN PROCTER LLP |
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024